We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

31 hedge funds and large institutions have $135M invested in Avalo Therapeutics in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 2

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

97% more capital invested

Capital invested by funds: $68.3M → $135M (+$66.4M)

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

55% more funds holding

Funds holding: 20 → 31 (+11)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

Holders
31
Holders Change
+11
Holders Change %
+55%
% of All Funds
0.67%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
13
Increased
8
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$3.11M
2
BFM
Boothbay Fund Management
New York
+$1.75M
3
AC
Armistice Capital
New York
+$913K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$703K
5
Millennium Management
Millennium Management
New York
+$688K

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$1M
2
Invesco
Invesco
Georgia
-$180K
3
OSAM
O'Shaughnessy Asset Management
Connecticut
-$118K
4
PC
PA Capital
Virginia
-$54K
5
BlackRock
BlackRock
New York
-$29.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$107M +$913K +61 +1%
OM
2
Opaleye Management
Massachusetts
$13.4M +$598K +40 +5%
EAM
3
Eventide Asset Management
Massachusetts
$3.5M +$3.11M +208 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.53M +$703K +47 +46%
BFM
5
Boothbay Fund Management
New York
$1.97M +$1.75M +117 New
Millennium Management
6
Millennium Management
New York
$861K +$688K +46 +920%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$731K +$150K +10 +30%
PM
8
Prosight Management
Texas
$665K -$1M -67 -63%
EI
9
EAM Investors
California
$653K +$583K +39 New
Invesco
10
Invesco
Georgia
$540K -$180K -12 -27%
SIM
11
Spark Investment Management
New York
$484K +$165K +11 +61%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$329K +$299K +20 New
Barclays
13
Barclays
United Kingdom
$319K +$284K +19 New
Goldman Sachs
14
Goldman Sachs
New York
$246K +$224K +15 New
Northern Trust
15
Northern Trust
Illinois
$222K +$89.8K +6 +86%
TEE
16
Tibra Equities Europe
United Kingdom
$210K +$180K +12 New
BCM
17
BlueCrest Capital Management
Jersey
$194K +$29.9K +2 +20%
BlackRock
18
BlackRock
New York
$170K -$29.9K -2 -17%
VF
19
Virtu Financial
New York
$109K +$105K +7 New
Citigroup
20
Citigroup
New York
$107K +$89.8K +6 New
Cambridge Investment Research Advisors
21
Cambridge Investment Research Advisors
Iowa
$99K -$15K -1 -14%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$85K -$15K -1 -17%
ECM
23
ExodusPoint Capital Management
New York
$77K +$74.8K +5 New
PAM
24
Panagora Asset Management
Massachusetts
$66K – – –
JP Morgan Chase
25
JP Morgan Chase
New York
$60K +$59.8K +4 New
1
2

AVTX Hedge Fund Activity: Q1 2019 in Review

31 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2019, worth a combined $135M — up 97% from $68.3M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AVTX positions and 2 closed out — a net gain of 11 holders — while 8 added to existing stakes and 5 trimmed.

The largest buyer was Eventide Asset Management, opening a new position worth an estimated $3.11M. The largest seller was Prosight Management, cutting an estimated $1M.

  • 31 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2019, up from 20 in Q4 2018.
  • Funds reported $135M of Avalo Therapeutics stock for Q1 2019, up 97% quarter-over-quarter.
  • 13 funds opened new Avalo Therapeutics positions in Q1 2019 and 2 closed out, a net change of +11 holders.
  • The largest Avalo Therapeutics buyer in Q1 2019 was Eventide Asset Management, an estimated $3.11M added.
  • The largest Avalo Therapeutics seller in Q1 2019 was Prosight Management, an estimated $1M sold.

Based on aggregated 13F filings for Q1 2019.